Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2 Open-Label, Dose-Escalation and Clinical Response Study of Quaratusugene Ozeplasmid in Combination With Osimertinib in Patients With Advanced, Metastatic EGFR-Mutant, Metastatic Non-Small Cell Lung Cancer

NCT04486833 is registered in ClinicalTrials.gov with Genprex, Inc. as lead sponsor.

NCT NCT04486833
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04486833 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2 Open-Label, Dose-Escalation and Clinical Response Study of Quaratusugene Ozeplasmid in Combination With Osimertinib in Patients With Advanced, Metastatic EGFR-Mutant, Metastatic Non-Small Cell Lung Cancer
Lead sponsor
Genprex, Inc.
Phase
Phase 1/2
Overall status
Recruiting
Start date
September 3, 2021
Completion date
March 31, 2029
Enrollment
158 (estimated)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

carcinoma, non-small cell lung